Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Losartan and E3174 pharmacokinetics in cytochrome P450 2C91/1, 1/2, and 1/3 individuals.

Pharmacotherapy - 1 Jun 2003

Lee Craig R, Pieper John A, Hinderliter Alan L, Blaisdell Joyce A, Goldstein Joyce A

Abstract excerpt

STUDY OBJECTIVE: To determine if differences in the pharmacokinetics of losartan and its pharmacologically active E3174 metabolite exist among individuals expressing the cytochrome P450 (CYP) 2C9*1/*1, *1/*2, and *1/*3 genotypes. DESIGN: Single-dose pharmacokinetic study. SETTING: University general clinical research center. SUBJECTS: Fifteen healthy volunteers, five from each genotype: CYP2C9*1/*1, *1/*2, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Half-Life

Share to Imidazoles

Share to Inactivation, Metabolic

Share to Losartan

Share to Tetrazoles

Source

Identifiers

PMID: 12820813
DOI: 10.1592/phco.23.6.720.32187

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.PMID 12820813Read ↗

Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.Semantic proximity Read ↗

Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.Semantic proximity Read ↗

[Association between cytochrome p4502c9 polymorphisms and losartan dosing in hypertensive patients].Semantic proximity Read ↗

Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes.Semantic proximity Read ↗

Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.Semantic proximity Read ↗

CYP2C9 genetic variants and losartan oxidation in a Turkish population.Semantic proximity Read ↗

CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.Semantic proximity Read ↗

The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendationsSemantic proximity Read ↗

Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.Semantic proximity Read ↗

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.Semantic proximity Read ↗

CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men.Semantic proximity Read ↗

Clinical consequences of cytochrome P450 2C9 polymorphisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.